{"id":"W3043703771","doi":"10.1056/nejmoa1910836","title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3708,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Eisai; National Institute for Health and Care Research; Plexxikon; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Sanofi Genzyme; Pfizer; Incyte; National Cancer Institute; LEO Pharma; Massachusetts Medical Society; Regeneron Pharmaceuticals; Sanofi; GlaxoSmithKline; Amgen; Les Laboratories Pierre Fabre; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Melanoma; Medicine; Oncology; Internal medicine; Metastatic melanoma; Immunotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001682867,0.0005152463,0.00119788,0.0005386737,0.0002182818,0.0003752849,0.0003761035,0.0004292729,0.001129302],"category_scores_gemma":[0.0008856901,0.0001652863,0.001080805,0.0002839851,0.0004058807,0.0003360049,0.0004542085,0.0008451946,0.0001406892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005503133,"about_ca_system_score_gemma":0.0004863887,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006720931,"about_ca_topic_score_gemma":0.001003354,"domain_scores_codex":[0.9994071,0.0002882732,0.00004107045,0.00008664815,0.00007825971,0.00009866674],"domain_scores_gemma":[0.9994747,0.0001341806,0.00008952159,0.00004158292,0.00002485683,0.0002351622],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7376485,0.01128726,0.04143576,0.0006621447,0.002331374,0.0001944145,0.0001337383,0.009689346,0.02450717,0.0002485419,0.0008402108,0.1710215],"study_design_scores_gemma":[0.1503393,0.6605682,0.1631439,0.0001474422,0.003591222,0.0003957543,0.00006542814,0.008953174,0.008569658,0.0009178232,0.003251208,0.00005689035],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958735,0.003049785,0.0002604394,0.00009111652,0.00005438627,0.00008316676,0.00008280967,0.00001514519,0.0004897643],"genre_scores_gemma":[0.9986886,0.0005929051,0.0002125314,0.00005786336,0.00005303468,0.0000859227,0.0001083717,0.000002085954,0.0001988572],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001682867,"threshold_uncertainty_score":0.008899927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007370799521923161,"score_gpt":0.2433068734822652,"score_spread":0.235936073960342,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}